Here is the math that makes Moderna’s two-day collapse worth examining carefully. Moderna’s stock had more than tripled to about $246 since August, lifting its market value to roughly $90 billion at the highs. Then an embargo breach on Thursday sent it down about 18%. Shares fell another roughly 6% toward $191 in Friday’s pre-market session. All of that happened while the underlying clinical result, a 42% reduction in the risk of recurrence or death, stayed exactly the same.
The structure of the selloff matters. Screenshots of the findings leaked on social media Thursday, and ESMO lifted the embargo after the breach. The market reacted to a leaked snapshot before most investors had read the full dataset. That sequence, panic first, analysis later, created the situation investors are navigating today.
What the Data Actually Shows
The Phase 3 INTerpath-001 trial evaluated intismeran autogene, an mRNA-based individualized neoantigen therapy, in combination with Keytruda as adjuvant treatment for patients with completely resected stage IIB-IV melanoma. The combination cut the relative risk of disease recurrence or death by 42% compared to Keytruda alone after a median of 24.6 months. That number disappointed investors anchored to the earlier Phase 2 readout. In the five-year follow-up presented in 2026, the earlier study showed a 49% reduction in the risk of recurrence or death.
But the 42% headline figure understates what happened after the vaccine fully primed patients’ immune systems. A pre-specified sensitivity analysis from six months onward, after the intismeran immunization regimen was complete, showed the combination reduced the risk of recurrence or death by 58% and reduced the risk of distant metastasis or death by 50% compared to Keytruda alone. That post-priming effect is arguably the number that will matter most to oncologists making prescribing decisions. After two years, 82% of patients receiving intismeran plus Keytruda were still alive without recurrence, versus 70% in the Keytruda-alone arm.
The Valuation Argument
BMO Capital Markets wrote that investors were looking for the data to demonstrate benefit in melanoma but also read across to other tumor types, and concluded that the results were “not enough to drive confidence amidst elevated expectations.” That framing is the bear case in a sentence: the stock had priced in platform validation, not just a melanoma approval.
The bull case starts from where the stock sits now. Barclays analysts have estimated that intismeran could generate around $3 billion in annual melanoma sales by 2035. Merck and Moderna share costs and any profits equally, so Moderna’s share of that figure would be roughly $1.5 billion from melanoma alone. Analysts who are modeling a larger revenue ramp over the next several years are implicitly assuming intismeran works in cancers beyond melanoma. The company has said it has eight total Phase 2 and Phase 3 trials underway for intismeran across multiple tumor types including non-small cell lung cancer, bladder cancer, and renal cell carcinoma. The ESMO data does nothing to impair those trials.
What Else You Are Buying
Intismeran is not the whole company. Moderna’s pipeline includes respiratory vaccines, latent-virus vaccines, oncology, and rare disease programs, and the company has also highlighted investments in early cell-therapy work, including in vivo approaches. The respiratory franchise includes multiple commercial products, and following positive Phase 3 readouts, Moderna completed regulatory submissions for its flu vaccine (mRNA-1010) in the U.S., Canada, Australia, and Europe. A flu approval in the near term would add a recurring revenue stream that has nothing to do with personalized cancer vaccines.
The Risks
Overall survival data from INTerpath-001 is not yet mature. Until it is, regulators and physicians have no proof the recurrence benefit translates into patients living longer. Pricing and reimbursement for a personalized, manufactured-to-order vaccine remain unresolved. Moderna’s long-term valuation cannot depend entirely on one melanoma treatment; the company still needs its other oncology programs and non-COVID products to deliver meaningful results.
Bottom Line
The 42% recurrence reduction in a 1,137-patient Phase 3 trial is approvable data. Whether it is practice-changing depends on the post-priming efficacy data and, eventually, overall survival. What the market is debating is legitimate. What it did in two days, wiping out on the order of $20 billion to $25 billion in market value on a leak-driven reaction, created a price that now asks a different question: at roughly $200 a share, how much of the intismeran approval is already discounted, and how much of everything else has the market discarded along with it?
